Several clinical scenarios warrant discussion: You should consider speaking with your GP if: You have type 2 diabetes that is inadequately controlled despite lifestyle modifications and metformin therapy, and your HbA1c remains above target You are struggling with weight management despite optimised thyroid hormone replacement, and you might meet NICE criteria for medical weight management (typically requiring referral to specialist weight management services) You have cardiovascular disease alongside type 2 diabetes, as some GLP-1 agonists (semaglutide, liraglutide, dulaglutide) have demonstrated cardiovascular benefits Your current diabetes medications are causing problematic side effects or hypoglycaemia Before your appointment , it is helpful to: Ensure your thyroid function has been checked recently (within the past 6 months) Compile a list of all current medications, including levothyroxine dose and timing Document your weight history and any previous weight management attempts Note any family history of thyroid cancer or endocrine conditions Prepare questions about potential benefits, risks, and alternatives Your GP will assess your suitability for GLP-1 therapy by reviewing your medical history, current thyroid status, diabetes control (if applicable), and overall health
197 The specific vulnerability of RGCs to OPA1 mutations remains unclear
The potential covariates included source, carnitine dosage, initial body weight, and age
They are legal but allowed only in certain circumstances, like if a patient has an allergy to an inactive ingredient in a branded drug or if a drug is in shortage
As discussed, one of its primary roles is to carry long-chain fatty acids to the mitochondria to be broken down for energy
This article reviews the strong association between selenium and thyroid disease and provides new ideas for the clinical management of selenium in thyroid disease
